Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet, page-65

Sadly, mate, the A*STAR aspect is what piqued my recollection to IVQ with OSX sharing many with similarities to the delisted entity which also had ties (a JV) with the Singaporean Science Agency. There are other factors that run parallel to IVQ too which I’m averse to getting into here as they are two different businesses, suffice to say that I’m a little more averse to investing in offshore subsidiaries (from certain countries) that established a parent company in OZ for the sole purpose of listing here. Ergo; it means I missed out on trades like DRO which I saw at 19c, but that’s part of my personal preference after being burnt with IVQ.

The tech seems good, and they have certain other clearances in place, but they fail in criteria for me personally.

Osteopore needs to follow OCC’s footsteps and rid themselves of the license fees shackled to Singapore’s NTU & NUS universitiesfor starters.

Sincerely hope this shoots the lights out for you all.